levothyroxine
Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
POWDER FOR INJECTION, INTRAVENOUS | 100 mcg (0.1 mg) | Restricted | ||||||||||
TABLET, ORAL | 25 mcg (0.025 mg); 50 mcg (0.05 mg); 75 mcg (0.075 mg); 88 mcg (0.088 mg); 100 mcg (0.1 mg); 112 mcg (0.112 mg); 125 mcg (0.125 mg); 137 mcg (0.137 mg); 150 mcg (0.15 mg); 175 mcg (0.175 mg); 200 mcg (0.2 mg) |
IV Levothyroxine should be reserved for myxedema patients, LOPA patients, pediatrics, or if a patient is NPO for a prolonged period. If IV Levothyroxine is indicated, please confirm correct dosing conversion.